Synonyms: AKCEA-APOCIII-LRX | IONIS-APOCIII-LRX | ISIS-678354 | ISIS-APOCIII-LRX | Tryngolza®
olezarsen is an approved drug (FDA (2024))
Compound class:
Nucleic acid
Comment: Olezarsen is an antisense GalNAc3-conjugated oligonucleotide (ASO) that targets the messenger RNA for apolipoprotein C-III (APOC3) as a mechanism to treat dyslipidemias [1-3,5]. The nucleotide sequence is chemically modified to optimise in vivo stability and hepatic delivery. We have been unable to resolve a full SMILES or HELM notation for the entire ASO.
|
Classification ![]() |
|
Compound class | Nucleic acid |
Compound subclass | Antisense oligonucleotide (ASO) |
Target | apolipoprotein C-III (APOC3) mRNA |
Approved drug? | Yes. FDA (2024) |
International Nonproprietary Names ![]() |
|
INN number | INN |
11801 | olezarsen |
Synonyms ![]() |
AKCEA-APOCIII-LRX | IONIS-APOCIII-LRX | ISIS-678354 | ISIS-APOCIII-LRX | Tryngolza® |
Database Links ![]() |
|
CAS Registry No. | 2097587-83-0 (source: WHO INN record) |
DrugBank Ligand | DB18728 |
GtoPdb PubChem SID | 507750292 |
Search PubMed clinical trials | olezarsen |
Search PubMed titles | olezarsen |
Search PubMed titles/abstracts | olezarsen |